miglitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1806 72432-03-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • miglitol
  • diastabol
  • seibule
  • glyset
Miglitol is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus.
  • Molecular weight: 207.23
  • Formula: C8H17NO5
  • CLOGP: -1.26
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 5
  • TPSA: 104.39
  • ALOGS: 0.47
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.68 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 610 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.035 Moderate 0.68
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.324 Moderate 0.68
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.615 10^-6 cm/s Moderate 0.68
dh-clint Dog hepatocyte intrinsic clearance 0.857 uL/min/10^6 cells Moderate 0.68
dppb Dog plasma protein binding (% unbound) 89.270 % Moderate 0.68
fcs-ppb Fetal calf serum protein binding (% unbound) 80 % Moderate 0.68
herg hERG pIC50 4.464 pIC50 Moderate 0.68
hh-clint Human hepatocyte intrinsic clearance 1.019 uL/min/10^6 cells Moderate 0.68
hlm-clint Human liver microsomal intrinsic clearance 3.373 uL/min/mg protein Moderate 0.68
hppb Human plasma protein binding (% unbound) 80.250 % Moderate 0.68
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,STK33,TEK,TGFBR1 28
kinase-selectivity-class ACVRL1,AXL,BMX,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,EIF2AK3,EPHB4,IGF1R,INSR,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K14,MAP3K21,PIK3CB,PIK3CD,TGFBR1,ZAP70 28
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.359 Moderate 0.68
mh-clint Mouse hepatocyte intrinsic clearance 0.546 Moderate 0.68
mppb Mouse plasma protein binding (% unbound) 94.320 Moderate 0.68
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.740 Moderate 0.68
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 93.880 % Moderate 0.68
rh-clint Rat hepatocyte intrinsic clearance 1.005 uL/min/10^6 cells Moderate 0.68
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.350 % Moderate 0.68
rppb Rat plasma protein binding (% unbound) 93.490 % Moderate 0.68
solubility-dd Solubility at pH 7.4 in DMSO 881.049 uM Moderate 0.68

Approvals:

DateAgencyCompanyOrphan
Dec. 18, 1996 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 102.04 39.08 34 805 69814 90557794
Hepatic function abnormal 65.36 39.08 22 817 46266 90581342
Cerebral infarction 64.03 39.08 19 820 26577 90601031
Hypoglycaemic encephalopathy 46.96 39.08 7 832 334 90627274
Pemphigoid 42.84 39.08 11 828 9015 90618593
Diabetic ketoacidosis 40.01 39.08 13 826 24394 90603214

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 89.46 28.73 45 1679 59809 42559802
Diabetes mellitus inadequate control 68.12 28.73 25 1699 15365 42604246
Hepatic function abnormal 63.28 28.73 34 1690 51533 42568078
Liver disorder 42.69 28.73 24 1700 39620 42579991
Renal impairment 39.79 28.73 34 1690 110194 42509417
Cerebral infarction 39.44 28.73 21 1703 31148 42588463
Glycosylated haemoglobin increased 32.60 28.73 14 1710 12910 42606701

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 168.06 26.16 73 2621 116031 110470574
Hepatic function abnormal 145.18 26.16 61 2633 89234 110497371
Diabetes mellitus inadequate control 105.53 26.16 36 2658 29739 110556866
Cerebral infarction 89.47 26.16 37 2657 51801 110534804
Pemphigoid 62.71 26.16 22 2672 19685 110566920
Glycosylated haemoglobin increased 62.50 26.16 23 2671 23596 110563009
Renal impairment 60.33 26.16 44 2650 188401 110398204
Pneumatosis intestinalis 53.76 26.16 16 2678 8513 110578092
Ketosis 44.62 26.16 10 2684 1744 110584861
Hyperglycaemia 44.50 26.16 27 2667 85063 110501542
Anti-insulin antibody positive 41.28 26.16 7 2687 284 110586321
Liver disorder 40.54 26.16 31 2663 142212 110444393
Platelet count decreased 38.57 26.16 37 2657 230406 110356199
Diabetic ketoacidosis 37.57 26.16 19 2675 42039 110544566
Hypoglycaemic encephalopathy 35.02 26.16 7 2687 706 110585899
Decreased appetite 33.49 26.16 49 2645 475797 110110808
Pancreatic carcinoma 30.39 26.16 12 2682 14860 110571745
Interstitial lung disease 28.40 26.16 25 2669 139309 110447296
Rectal cancer 27.80 26.16 8 2686 3781 110582824
Diabetes mellitus 26.85 26.16 21 2673 99360 110487245
Altered state of consciousness 26.85 26.16 17 2677 57609 110528996

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BF02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Alpha glucosidase inhibitors
FDA MoA N0000000166 alpha Glucosidase Inhibitors
FDA EPC N0000175559 alpha-Glucosidase Inhibitor
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D065089 Glycoside Hydrolase Inhibitors
CHEBI has role CHEBI:35526 hypoglycemic agent

Related Drugs by ATC class:

A10BF Alpha glucosidase inhibitors 2 drugs
acarbosevoglibose

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Infectious disease contraindication 40733004
Ulcerative colitis contraindication 64766004 DOID:8577
Ulceration of intestine contraindication 85942002
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Hypoglycemic disorder contraindication 237630007
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Prolonged-Severe Nausea and Vomiting contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.55 acidic
pKa2 7.11 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Lysosomal alpha-glucosidase Enzyme INHIBITOR IC50 6.46 CHEMBL CHEMBL
Maltase-glucoamylase, intestinal Enzyme INHIBITOR Ki 6 CHEMBL CHEMBL
Glucosylceramidase Enzyme IC50 4.08 CHEMBL
Sucrase-isomaltase, intestinal Enzyme IC50 6.30 CHEMBL
Lactase-phlorizin hydrolase Enzyme IC50 4.30 CHEMBL
Pancreatic alpha-amylase Enzyme WOMBAT-PK
Sucrase-isomaltase, intestinal Enzyme IC50 6.96 CHEMBL
Lysosomal alpha-glucosidase Enzyme Ki 6.34 CHEMBL
Glycogen debranching enzyme Enzyme IC50 6.41 CHEMBL
Beta-galactosidase Enzyme Ki 4 CHEMBL
Alpha-mannosidase Enzyme IC50 4.12 CHEMBL
Alpha-glucosidase Enzyme IC50 4.24 CHEMBL

External reference:

IDSource
4021063 VUID
N0000148526 NUI
D00625 KEGG_DRUG
4021063 VANDF
C0066535 UMLSCUI
CHEBI:6935 CHEBI
MIG PDB_CHEM_ID
CHEMBL1561 ChEMBL_ID
DB00491 DRUGBANK_ID
441314 PUBCHEM_CID
C045621 MESH_SUPPLEMENTAL_RECORD_UI
4842 IUPHAR_LIGAND_ID
5879 INN_ID
0V5436JAQW UNII
217372 RXNORM
14051 MMSL
241455 MMSL
7945 MMSL
d04110 MMSL
007635 NDDF
109071007 SNOMEDCT_US
386046009 SNOMEDCT_US
0V5436JAQW INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 69367-303 TABLET, COATED 25 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 69367-304 TABLET, COATED 50 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 69367-305 TABLET, COATED 100 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 71205-935 TABLET, COATED 25 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 71205-936 TABLET, COATED 50 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 71205-937 TABLET, COATED 100 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 76333-125 TABLET, COATED 25 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 76333-126 TABLET, COATED 50 mg ORAL ANDA 25 sections
Miglitol HUMAN PRESCRIPTION DRUG LABEL 1 76333-127 TABLET, COATED 100 mg ORAL ANDA 25 sections